LONG-TERM ADMINISTRATION OF HEPARIN AND HEPARIN FRACTIONS AND OSTEOPOROSIS IN EXPERIMENTAL-ANIMALS

被引:35
作者
MURRAY, WJG [1 ]
LINDO, VS [1 ]
KAKKAR, VV [1 ]
MELISSARI, E [1 ]
机构
[1] THROMBOSIS RES INST,LONDON SW3 6LR,ENGLAND
关键词
BONE DEMINERALIZATION; OSTEOPOROSIS; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; HIGH MOLECULAR WEIGHT HEPARIN; BONE CORTICAL THICKNESS; FEMORAL FRAGILITY;
D O I
10.1097/00001721-199504000-00004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To test whether heparin-induced osteoporosis is influenced by the molecular weight of heparin, 24 male rabbits received single daily subcutaneous injections of either physiological saline (controls, n = 5), low molecular weight heparin (LMWH, n = 7), conventional heparin (UFH, n = 7) or high molecular weight heparin (HMWH, n = 6). Heparin was administered in supratherapeutic daily dosages for 120 days (750 anti-FXa units/kg for 90 days and 1500 anti-FXa units/kg for another 30 days). Studied variables were: serial analysis of serum calcium, albumin, phosphate and alkaline phosphatase, measurement of the cortical thickness of the femur (radiographically), tibial and trabecular bone density (both by cross-sectional analysis) and femoral fragility. Observed changes in blood biochemistry associated with bone metabolism were not correlated to any of the treatments. Compared with the controls, a reduction in cortical and trabecular bone density was seen with UFH (P < 0.05) and HMWH(P < 0.01) but not with LMWH. Femoral fragility was also significantly increased (P < 0.002) by HMWH. In conclusion, LMWH did not cause toxic skeletal effects as opposed to HMWH which clearly did, and UFH which induced some osteoporotic changes.
引用
收藏
页码:113 / 118
页数:6
相关论文
共 18 条
[1]  
AARSKOG D, 1980, BLOOD, V20, P650
[2]  
BUCHWALD H, 1980, SURGERY, V88, P507
[3]  
DESWIET M, 1983, BRIT J OBSTET GYNAEC, V90, P1129
[4]  
GRIFFITHS HT, 1989, POSTGRAD MED J, V60, P424
[5]   LONG-TERM THERAPY WITH SUBCUTANEOUS HEPARIN DURING PREGNANCY [J].
HELLGREN, M ;
NYGARDS, EB .
GYNECOLOGIC AND OBSTETRIC INVESTIGATION, 1982, 13 (02) :76-89
[6]   THE RISKS OF ANTENATAL SUBCUTANEOUS HEPARIN-PROPHYLAXIS - A CONTROLLED TRIAL [J].
HOWELL, R ;
FIDLER, J ;
LETSKY, E ;
DESWIET, M .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1983, 90 (12) :1124-1128
[7]   NONHEMORRHAGIC COMPLICATIONS OF ANTICOAGULANT-THERAPY [J].
LEVINE, MN .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1986, 12 (01) :63-66
[8]  
MATZSCH T, 1990, THROMB HAEMOSTASIS, V63, P505
[9]  
MEGARD M, 1982, NOUV PRESSE MED, V11, P261
[10]  
MELISSARI E, 1992, THROMB HAEMOSTASIS, V68, P652